skip to primary navigationskip to content

Funding and Research Grants

Funding and Research Grants


SMRI The Stanley Medical Research Institute (SMRI) is a nonprofit organization supporting research into schizophrenia and bipolar disorder. Since it began in 1989, SMRI has supported more than $600 million in research in over 30 countries around the world. It is the largest nongovernmental source of funds for research on these diseases in the United States.

Myriad RBM

Myriad RBM is the world’s leading multiplexed immunoassay testing laboratory, providing comprehensive protein biomarker services based on its Multi-Analyte Profiling (MAP) technology platform. This platform provides pre-clinical and clinical researchers with reproducible and quantitative data for multiplexed testing of hundreds of molecular analytes in a cost-effective manner.

Myriad Genetics

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patient’s lives through the discovery and commercialization of transformative tests to assess a person’s risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence.


Psynova Neurotech is exclusively focused on the commercial development and exploitation of novel biomarkers and drug targets for Neuropsychiatric and other mental illnesses.


The BBSRC has a unique and central place in supporting the UK’s world-leading position in bioscience. They are an investor in research and training, with the aim of furthering scientific knowledge, to promote economic growth, wealth and job creation and to improve quality of life in the UK and beyond.



The Engineering and Physical Sciences Research Council (EPSRC) is the UK’s main agency for funding research in engineering and the physical sciences. EPSRC invests around £800 million a year in research and postgraduate training, to help the UK to handle the next generation of technological change.
NESDA The Netherlands Study of Depression and Anxiety (NESDA) was designed to investigate the course of depression and anxiety disorders over a period of several years. It includes 2981 participants with and without symptoms from primary care practices and specialised mental health institutions.


The aim of TACTICS is to identify the neural, genetic and molecular factors involved in the pathogenesis of compulsivity. A strong multidisciplinary team of preclinical and clinical top researchers all work together to a better understanding and treatment of the syndromes. TACTICS is a project funded by the EU programme FP7 and combines 11 partners from 7 different countries.
autism speaks Autism Speaks supports global biomedical research into the diagnosis, causes, prevention, and treatment of autism or its disabling symptoms. Their mission is to improve the future for all who struggle with autism spectrum disorders. In support of that mission they provide funding along the entire research continuum - from discovery to development to dissemination - for innovative projects that hold considerable promise for significantly improving the lives of those affected by autism.
FP7 The current diagnosis of psychiatric disorders such as schizophrenia and mood disorders, is highly subjective, due to the lack of empirical markers or objective tests specific for these diseases. PSYCH-AID searchers to fill the gap through the in-parallel study of schizophrenia and mood disorder patients combining, validating and registering 4 sets of biomarker tests already in advanced stage of development.